Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13494362 | 0.87 | PTGS1 (0.30) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL12680246 | 0.87 | PTGS1 (0.30) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL13765228 | 0.86 | APP (0.39) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL13694506 | 0.81 | PTGS1 (0.33) | PTGS1PDE4A | |
| SCHEMBL26084391 | 0.80 | — | — | |
| SCHEMBL13231025 | 0.78 | APP (0.33) | APP | |
| SCHEMBL12226836 | 0.77 | — | — | |
| SCHEMBL14407786 | 0.76 | — | — | |
| SCHEMBL12190369 | 0.76 | — | — | |
| SCHEMBL14172469 | 0.73 | EPHX2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780834-B2 | Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3- yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use | GENENTECH, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230165876-A1 | METHYLTHIONINIUM COMPOUNDS FOR USE IN THE TREATMENT OF COVID-19 | WISTA LABORATORIES LTD. (SG) | 2023-06-01 | — | — | US | disclosed |
| US-20230165877-A1 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | WISTA LABORATORIES LTD. (SG) | 2023-06-01 | — | — | US | disclosed |
| US-8182581-B2 | use of these novel bis-cationic and/or bis-anionic ionic liquids as the stationary phase in a gas chromatographic column | SIGMA-ALDRICH CO. LLC (US) | 2012-05-22 | — | — | US | disclosed |
| US-8168830-B2 | use of these novel ionic liquids having bis-cation or bis-anion separated by bridging group as the stationary phase in a gas chromatographic column | SIGMA-ALDRICH CO. LLC (US) | 2012-05-01 | — | — | US | disclosed |
| US-7914965-B2 | Resist composition and method of pattern formation with the same | FUJIFILM CORPORATION (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20100305080-A1 | Novel Crystalline Salts of Montelukast | O'SHEA PAUL | 2010-12-02 | — | — | US | disclosed |
| US-20080275251-A1 | Novel Intermediates and Their Use | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-7429679-B2 | Sulphonic acid salt of sibutramine | CJ CORPORATION (KR) | 2008-09-30 | — | — | US | disclosed |
| US-20080027231-A1 | High stability diionic liquid salts | SIGMA-ALDRICH CO. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20070191481-A1 | Sulphonic acid salt of sibutramine | CJ CORPORATION (KR) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165876-A1 | METHYLTHIONINIUM COMPOUNDS FOR USE IN THE TREATMENT OF COVID-19 | ACE2, BHMT2, ICMT | PTGS1 1619/4885PDE4A 2653/4885LMNA 3014/4885 |
| US-20080027231-A1 | High stability diionic liquid salts | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDHD5, DAD1 | PTGS1 2682/4885PDE4A 3996/4885LMNA 739/4885 |
| US-20070191481-A1 | Sulphonic acid salt of sibutramine | GPR119, FABP6, HTR6 | PTGS1 2352/4885PDE4A 1872/4885LMNA 4391/4885 |
| US-20230165877-A1 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | ACHE, BCHE, PNMT | PTGS1 3666/4885PDE4A 759/4885LMNA 4703/4885 |
| US-11780834-B2 | Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3- yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use | TP53, DPYD, FLI1 | PTGS1 1521/4885PDE4A 3963/4885LMNA 2912/4885 |
| US-20100305080-A1 | Novel Crystalline Salts of Montelukast | LTC4S, CYSLTR1, CYSLTR2 | PTGS1 31/4885PDE4A 1285/4885LMNA 3721/4885 |
| US-20080275251-A1 | Novel Intermediates and Their Use | PLEC, NISCH, ALK | PTGS1 2412/4885PDE4A 995/4885LMNA 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.